Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Open-Label Phase IV Study to Evaluate Overall Health, Physical Activity, and Joint Outcomes, in Participants Aged ≥13 and <70 Years With Severe or Moderate Hemophilia A Without FVIII Inhibitors on Emicizumab Prophylaxis

NCT05181618 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT05181618
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05181618 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Open-Label Phase IV Study to Evaluate Overall Health, Physical Activity, and Joint Outcomes, in Participants Aged ≥13 and <70 Years With Severe or Moderate Hemophilia A Without FVIII Inhibitors on Emicizumab Prophylaxis
Lead sponsor
Hoffmann-La Roche
Phase
Phase 4
Overall status
Active, not recruiting
Start date
June 20, 2022
Completion date
November 30, 2027
Enrollment
136 (actual)
Sites
28

Conditions

As the registry lists them; a condition with its own page is linked.

moderate hemophilia a, severe hemophilia a